Smoore International Not Listed as Huabao's Main Client

Business by 2FIRSTS.ai

Dec.06.2023

Smoore International Not Listed as Huabao's Main Client

Huabao Shares denies Smoore International as its main client, clarifies on investor platform.

An investor asked on the investor interaction platform: Is Smoore International the company's main client?

Huabao Group (300741.SZ) stated on December 4th on an investor interaction platform that Smoore International is currently not included among the company's main clients.

Also Read:

[1] Smoore Announces FEELM 2.0: Double the Puffs, Half the Cost

[2] Smoore International Reports Decreased Financial Performance in 2023

#Asia #Market #China #smoore #International

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Al Fakher Parent Company Plans U.S. Listing in 2026 at $1.75 Billion Valuation

According to Bloomberg, Dubai-based hookah brand owner Advanced Inhalation Rituals (AIR) plans to go public on Nasdaq in the first half of 2026 through a merger with a Cantor Fitzgerald-backed SPAC. The deal values the combined company at USD 1.75 billion under the ticker “AIIR.”

Nov.11

5th Circuit Reviews FDA’s Compliance on Small-Business Impact of Vape Rule

A Fifth Circuit panel expressed doubts about whether the U.S. Food and Drug Administration complied with the Regulatory Flexibility Act when issuing its 2021 final rule on premarket tobacco product applications. Vape companies argued the FDA relied on outdated and inaccurate economic data, while the government said the challenged requirements stem from the Tobacco Control Act.

Dec.03 by 2FIRSTS.ai

BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%

BAT Rothmans introduces "glo hyper" series promotion in South Korea, with "glo hyper pro" for $20 and "glo hyper" for $14.

Oct.15 by 2FIRSTS.ai

1,200 Health Leaders Urge UK Parliament to Pass Tobacco and Vapes Bill Swiftly

Over 1,200 UK health leaders urged Parliament to pass the Tobacco and Vapes Bill quickly, calling it vital to protect future generations. The bill would ban tobacco sales to anyone born after Jan 1, 2009, and restrict vape packaging and flavours. Health groups warned delays risk undermining “gamechanging” public health reforms.